bzgl. GNTA
http://ih.advfn.com/...814413&article=36259966&symbol=NB^GNTA**************************************************
Seite_30:
AS: 6,000,000,000 shares
Einleitung:
As of February 4, 2009, the registrant had 946,497,242 shares of Common Stock outstanding
Seite_27:
At December 31, 2008, we had 486.7 million shares of common stock outstanding
==> Anmerkung von mir: fast eine Verdopplung der ausgegebenen Aktien in 35 Tagen!
**************************************************
Seite_20:
We anticipate that we will incur additional losses and we may never be profitable.
We have never been profitable. We have incurred substantial annual operating losses associated with ongoing research and development activities, preclinical testing, clinical trials, regulatory submissions and manufacturing activities. From the period since our inception to December 31, 2008, we have incurred a cumulative net deficit of $944.1 million. We may never achieve revenue sufficient for us to attain profitability.
Achieving profitability is unlikely unless Genasense ® receives approval from the FDA or EMEA for commercial sale in one or more indications.
If Genasense ® is not approved, if approval is significantly delayed, or if in the event of approval the product is commercially unsuccessful, we do not expect significant sales of other products to offset this loss of potential revenue.
**************************************************
Seite_42:
Net loss
Genta incurred a net loss of $505.8 million, or $9.10 per share, for 2008, $23.3 million, or $0.79 per share, for 2007 and $56.8 million, or $2.52 per share, for 2006.
**************************************************
Seite_53:
(In thousands, except per share data) 2008 2007 2006
Net loss
$ (505,838 ) $ (23,320 ) $ (56,781 )
Net loss per basic and diluted common share
$ (9.10 ) $ (0.79 ) $ (2.52 )